+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Sunitinib"

RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
From
From
From
From
From
Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) Drug Overview 2019 - Product Thumbnail Image

Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) Drug Overview 2019

  • Report
  • September 2019
  • 29 Pages
  • Global
Inlyta (axitinib; Pfizer) Drug Overview 2019 - Product Thumbnail Image

Inlyta (axitinib; Pfizer) Drug Overview 2019

  • Report
  • March 2019
  • 20 Pages
  • Global
Sutent (sunitinib; Pfizer) Drug Overview 2019 - Product Thumbnail Image

Sutent (sunitinib; Pfizer) Drug Overview 2019

  • Report
  • March 2019
  • 19 Pages
  • Global
From
Loading Indicator

Sunitinib is an oncology drug used to treat a variety of cancers, including gastrointestinal stromal tumors, renal cell carcinoma, and pancreatic neuroendocrine tumors. It is a tyrosine kinase inhibitor, meaning it works by blocking the action of certain proteins that can cause cancer cells to grow and divide. Sunitinib is typically administered orally, and is available in both capsule and tablet form. Sunitinib is a relatively new drug, having been approved by the US Food and Drug Administration in 2006. It has since become a popular treatment option for many types of cancer, due to its effectiveness and relatively low side effects. Sunitinib is also used in combination with other drugs to treat certain types of cancer, such as advanced renal cell carcinoma. Some of the companies in the Sunitinib market include Pfizer, Novartis, and AstraZeneca. These companies manufacture and distribute the drug, as well as provide support and resources for patients and healthcare professionals. Show Less Read more